Miyatake Akihiko, Fujita Mari, Nagasaka Yukio, Fujita Kimie, Tamari Mayumi, Watanabe Dai, Nakano Naoko, Hidari Kazuya I P J, Suzuki Yasuo
Miyatake Asthma Clinic, Osaka, Japan.
Allergol Int. 2007 Sep;56(3):231-9. doi: 10.2332/allergolint.O-06-444. Epub 2007 Jun 1.
Viral infection of the respiratory tract in patients with asthma is one of the most frequent causes of exacerbation of asthmatic symptoms. Disodium cromoglycate (DSCG) is a commonly used anti-asthmatic medicine with many beneficial biochemical and physiological effects. The purpose of this study was to investigate the efficacy of DSCG against colds when used in clinical practice.
A questionnaire survey to determine the efficacy of DSCG was undertaken in 220 adult patients with asthma (81 male, 139 female; mean age: 54.1 +/- 13.7 years and 60.1 +/- 12.7 years, respectively) from April to September 2004 at the Miyatake Asthma Clinic.
The duration of DSCG inhalation therapy was not less than 5 years in more than half of the patients. The mean daily DSCG dose at the time of the questionnaire survey was 40mg/day in over 50% of all patients. After DSCG was added to inhaled corticosteroid (ICS) combination therapy, 56.4% of the patients rated their condition as "improved", and 66.4% of the patients felt that the frequency of colds they had caught had decreased while DSCG was added to ICS.
DSCG inhalation therapy is a useful additional treatment following ICS to alleviate asthma symptoms, and to prevent colds in adult patients with asthma.
哮喘患者呼吸道的病毒感染是哮喘症状加重的最常见原因之一。色甘酸钠（DSCG）是一种常用的抗哮喘药物，具有许多有益的生化和生理作用。本研究的目的是调查DSCG在临床实践中用于预防感冒的疗效。
2004年4月至9月，在宫武哮喘诊所对220例成年哮喘患者（男性81例，女性139例；平均年龄分别为54.1±13.7岁和60.1±12.7岁）进行了一项问卷调查，以确定DSCG的疗效。
超过一半的患者DSCG吸入治疗时间不少于5年。在所有患者中，超过50%的患者在问卷调查时DSCG的平均每日剂量为40mg/天。在吸入性糖皮质激素（ICS）联合治疗中加入DSCG后，56.4%的患者将其病情评为“改善”，66.4%的患者感觉在ICS中加入DSCG后感冒次数减少。
DSCG吸入治疗是在ICS之后一种有用的辅助治疗方法，可缓解哮喘症状，并预防成年哮喘患者感冒。
